Who owns Caribou Biosciences, Inc. (CRBU)? Elite investor 13F holders
2 tracked elite investors reported holding Caribou Biosciences, Inc as of 2026-06-30, including Renaissance Technologies LLC, Maverick Capital. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | Caribou Biosciences Inc | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 4881439.00 USD | 2773545.000000 | Shares | add | Original filing |
| Maverick Capital | Caribou Biosciences Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1148474.00 USD | 652542.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.